WNT8A and Dravet syndrome: Several Wnt ligands (WNT4, WNT7B, WNT8A, and WNT10B), receptors (FZD5 and FZD8), and a gene involved in the Wnt signaling pathway (LEF1) were highly expressed, associated with the decrease in E-CAD after DS treatment (Fig. 6B).